Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks.

An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a Phase 3 study in the works.

Structure Therapeutics' oral obesity drug ​aleniglipron delivered up to 16.3% ‌weight loss when compared with a placebo after 44 weeks of ​treatment in a mid‑stage ​study, it said on Monday.

A new report indicates that 70% of diet pill users experience side effects, including severe issues like suicidal thoughts. The study, involving 257 participants aged 19 to 64, found that 60% were not ...

The study also raised concerns about the risks of prolonged use of diet pills. Read more at straitstimes.com. Read more at ...

Consumer-healthcare group Haleon said supplements to GLP-1 drugs were its best bet in winning a slice of the weight-loss market.

Scientists may be one step closer to the 'holy grail' of dieting — packing the weight loss effects of the keto diet into a single pill. The popular high-fat, low-carb diet forces the body into a ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Produce prescriptions and hospital food programs are expanding fast. But the real test isn’t medical—it’s financial.